Rosen Law Firm Files Class Action Lawsuit Against Actinium Pharmaceuticals
New York, NY – April 2, 2025
The Rosen Law Firm, a global investor rights law firm, has announced the filing of a class action lawsuit against Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) on behalf of purchasers of the company’s securities during the period from October 31, 2022, to August 2, 2024 (the “Class Period”).
Details of the Lawsuit
The complaint alleges that Actinium Pharmaceuticals and certain of its executives and directors made false and misleading statements and failed to disclose material information to the investing public, thereby violating the Securities Exchange Act of 1934.
According to the lawsuit, during the Class Period, Actinium Pharmaceuticals issued misleading statements regarding the commercial prospects of its lead product candidate, Actimab-A, and its financial performance. Specifically, the company reported higher sales and revenue than it actually generated, and it failed to disclose that it was experiencing significant declines in sales and revenue.
Impact on Individual Investors
The filing of this class action lawsuit may have significant implications for individual investors who purchased Actinium Pharmaceuticals securities during the Class Period. If the allegations in the lawsuit are proven, these investors may be entitled to compensation for their losses.
Global Implications
Beyond the individual investor level, the filing of this class action lawsuit against Actinium Pharmaceuticals could have wider implications for the biotech industry and the broader financial markets. It underscores the importance of transparency and accuracy in financial reporting and the potential consequences of misleading statements.
Additional Information from Online Sources
- According to reports, Actinium Pharmaceuticals’ stock price dropped significantly following the announcement of the lawsuit.
- The company has not yet responded to the allegations in the lawsuit.
- The Rosen Law Firm is known for its success in recovering damages for investors in securities fraud cases.
It is important to note that the filing of a class action lawsuit is not a guarantee of success, and the outcome of this case is uncertain.
Conclusion
The Rosen Law Firm’s filing of a class action lawsuit against Actinium Pharmaceuticals raises concerns about the accuracy and transparency of the company’s financial reporting during the Class Period. Individual investors who purchased Actinium Pharmaceuticals securities during this period may be entitled to compensation if the allegations in the lawsuit are proven. The case also highlights the importance of transparency and accuracy in financial reporting for all publicly traded companies.
As the legal proceedings unfold, it will be important for investors to stay informed about developments in this case and the broader implications for the biotech industry and the financial markets.
For more information, investors are encouraged to contact the Rosen Law Firm at (212) 614-5400 or by email at [email protected].
No Class has yet been certified in the above action.
THE ROSEN LAW FIRM’S CASE INFORMATION PAGE ON THESE CASES CAN BE FOUND AT: https://rosenlegal.com/cases-registered-by-the-rosen-law-firm/actinium-pharmaceuticals-inc-class-action-lawsuit-atnm/
Join us on Facebook: https://www.facebook.com/rosenlawfirm/
Follow us on Twitter: https://twitter.com/rosen_firm
Follow us on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm/
For all inquiries, please contact:
Laurence Rosen, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 614-5400
Fax: (212) 202-3827
Email: [email protected]
Web: https://rosenlegal.com
